在试点生物可用性/生物等价性研究中,Cmax生物等价性的预测潜力,通过替代 ƒ2相似性因子方法
Sara Carolina Henriques1,2, Paulo Paixão1, Luis Almeida2
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
Pharmaceutics
|October 28, 2023
概括
试点生物可用性/生物等价性研究可以使用几何平均值 (Gmean) f2因子来更好地做出决策. 这种方法有助于确定是否需要关键研究,特别是具有更高可变性的研究.
科学领域:
- 药理动力学和药物开发
- 生物制药科学 生物制药科学
- 监管科学 监管科学
背景情况:
- 试点生物可用性/生物等价性 (BA/BE) 研究是关键的临床试验,通常在没有正式样本大小计算的情况下招收12-18名受试者.
- 之前的工作建议使用几何平均值 (Gmean) f2因子用于试点BA/BE数据评估,显示在特定条件下对Cmax评估有希望.
研究的目的:
- 评估拟议的Gmean f2因子方法与标准平均生物等价值在更极端的场景的试点BA/BE研究.
- 评估Gmean f2因子在进行关键生物等价性研究的决策中的有用性.
主要方法:
- 模拟试点BA/BE交叉研究,使用种群药动力学建模,具有不同间场合变化 (IOV) 水平.
- 对比了Gmean f2因子与标准平均生物等价值在不同的真实几何平均比率 (GMRs) 生物等价和生物不等价配方.
主要成果:
- 建议重新定义决策树,建议在试点研究中使用20个受试者的固定的样本大小,当受试者内部变化系数 (ISCV%) >20%或未知时.
- 建议将Gmean f2因子方法与平均生物等价值一起使用,当GMR的90%置信区间落在 [80.00-125.00]%的接受范围之外时.
结论:
- 基于试点研究结果和可变性,Gmean f2因子方法为继续进行关键BA/BE研究的确定性提供了有价值的见解.
- 这种替代方法有助于优化关键生物等价性研究进展的决策,特别是在具有挑战性的变异性场景中.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Bioavailability: Overview
2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Pharmacokinetic Models: Comparison and Selection Criterion
79
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
79
Factors Influencing Bioavailability: First-Pass Elimination
6.4K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.4K
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
531
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
531
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
106
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
106


